

Colleagues,

Please find below the National Notifiable Diseases Surveillance System (NNDSS) Modernization Initiative (NMI) Technical Assistance (TA) Coordination Team Update for May 8, 2015. These e-mail updates are a collaboration among the Centers for Disease Control and Prevention (CDC), Council of State and Territorial Epidemiologists (CSTE), and the Association of Public Health Laboratories (APHL) and will be sent biweekly in an effort to keep reporting jurisdictions and other partners and stakeholders updated on the progress of NMI.

For more information on NMI, please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>. If you have questions not answered in the FAQs, please send them to edx@cdc.gov.

NNDSS Modernization Initiative Technical Assistance Coordination Team Update

May 8, 2015

NMI Overall Updates

- The NMI team held an orientation on 4/24/15 for CDC program subject matter experts (SMEs) associated with arboviral diseases and the conditions covered by the generic message. The presentation provided background on NMI so that SMEs new to the NMI process will be prepared to participate.
 - The Message Mapping Guide (MMG) Development Team plans to start work on the Arboviral MMG within the next month.
 - In addition, the NMI team expects to implement the Generic v2 MMG in June–July 2015 and will need input from CDC programs to validate messages.
- To improve users' experience with the NNDSS web site, the NNDSS program made several updates, launched on 4/29/15, at <http://wwwn.cdc.gov/nndss/>:
 - CDC applied responsive design to the NNDSS site. The responsive approach improves users' viewing experience by automatically optimizing the design for phones, tablets, laptops, or widescreen computers.
 - CDC added new text to the web site to describe the message restructuring effort.
 - In addition, CDC updated all of the MMG-related documents previously on the Draft MMG Web Site to reflect the message restructuring effort and also posted updated artifacts and related documentation.
- Staff members from all three NMI partners—CDC, CSTE, and APHL—plan to participate in several NMI-related sessions at the upcoming CSTE Annual Conference, to be held in Boston, Massachusetts, from 6/14/15 to 6/18/15. More information about these sessions will be provided soon.

Message Mapping Guide Development Updates

- The MMG Development Team determined the conditions included in the Generic v2 MMG.
 - Jurisdictions will be able to use the Generic v2 MMG for more than 50 conditions.
 - CDC will make the list of conditions available at a later date.
- **Message Mapping Guide Status Updates:**
 - **Mumps and Pertussis MMGs** ([Stage 1—Draft Phase](#))

- The MMG Development Team posted the restructured Mumps and Pertussis MMGs to the Draft MMG Web Site on 4/29/15. The second external review period of 3 weeks is from 4/29/15 to 5/22/15.
 - The MMG Development Team sent an external announcement about the second external review of the Mumps and Pertussis MMGs to CSTE for distribution to pilot jurisdictions and CSTE membership on 4/29/15.
 - CSTE will conduct a webinar for jurisdictions on 5/8/15 from noon to 1:00 PM about the summary of changes to the Mumps and Pertussis MMGs.
- **Congenital Syphilis and STD MMGs** ([Stage II—Pilot Test-ready Draft Phase](#))
 - The MMG Development Team posted pilot test-ready versions of the STD and Congenital Syphilis MMGs and their artifacts to the Draft MMG Web Site.
- **Generic v2 and Hepatitis MMGs** ([Stage II—Pilot Test-ready Draft Phase](#))
 - The MMG Development Team posted pilot test-ready versions of the Generic v2 and Hepatitis MMGs and their artifacts to the Draft MMG Web Site.
- No guides are in [Stage III—Final MMG Phase](#) at this time.

Message Validation, Processing, and Provisioning System Updates

- The Message Validation, Processing, and Provisioning System (MVPS) developer is currently finalizing the development of the message processing functions for Generic v2, Hepatitis, and STD requirements that CDC submitted to the developer on 4/3/15.
 - The developer and the MVPS requirements team currently are discussing implementation options for some of the data elements.
 - The developer is expected to deliver the message processing code to CDC in support of these requirements in May 2015.
- The MVPS Team delivered the Congenital Syphilis message processing guide (MPG) and processing requirements documents to the MVPS developer on 5/1/15.
- The MVPS Team continues to work on finalizing the data provisioning requirements and data dictionary mapping for Generic v2, Hepatitis, and STD in conjunction with the CDC Surveillance Operations Team (SOT) and the Message and Vocabulary (M&V) Team.
 - The MVPS Team reviewed the requirements with the NMI team members and discussed them with the MVPS developer this week.
 - The MVPS Team will schedule time with the CDC programs to discuss the data provisioning design and approach shortly thereafter.
- The MVPS developer delivered code for the MVPS Dashboard role-based security functionality to CDC on 4/17/2015, and CDC soon will begin internal technical validation testing of this functionality.
 - Role-based security will give both users internal to CDC and external to CDC role-based access to specific functions and data within the dashboard.
 - The MVPS Dashboard is a component of the MVPS that summarizes data sent by jurisdictions, including the details of messages received and processed by CDC and errors and warnings associated with messages that were submitted by jurisdictions. The dashboard also will allow jurisdictions to identify notifications that have been received successfully by MVPS or that may need rework, as well as to perform near real-time reconciliation of messages sent to and received by MVPS.

- The updated Message Evaluation and Testing Service (METS) tool is expected to be available in early June 2015 to support jurisdictions in their independent testing of Hepatitis, STD, and Generic v2 messages.
- The MVPS Dashboard and message processing functionality also is expected to be available in June 2015 to support independent testing of Generic v2, Hepatitis, and STD messages by the jurisdictions and programs.
 - The message processing functionality supports the implementation of the MMGs.

Technical Assistance Updates

- The APHL Technical Assistance (TA) Team continues to work with the pilot jurisdictions participating in the NMI TA Pilot Phase II, wave 1 (occurring now through 6/30/15).
 - The APHL TA Team was onsite this week at the California Department of Health, working on implementing the Generic v2, Hepatitis, and STD case notification messages. APHL will provide details about this site visit soon.
 - The team is scheduled to provide hands-on technical assistance to the Minnesota Department of Health the week of 5/11/15.
 - The team is scheduled to provide hands-on technical assistance to the Oregon Department of Health the week of 6/8/15.
 - Florida and Michigan continue to work virtually with the APHL TA Team to prepare for the implementation of the new case notification messages.
 - The New York Department of Health is serving as an independent pilot site for NMI and has received TA tools from the APHL TA Team. New York also will participate in the NMI evaluation process.
- APHL continues to develop and refine NMI TA tools and resources, including the Rhapsody route and Mirth channel for Hepatitis and STD.
- CSTE will work with all of the pilot jurisdictions to evaluate the NMI TA efforts.
- Reminder about MMG status:
 - MMGs in Stages I and II are considered draft and may be revised until the time they are finalized.
 - Those jurisdictions selected for pilot testing of the test-ready versions (Stage II) of the MMGs should wait until contacted by the NMI TA Team before using the test-ready MMGs, before implementing surveillance information system changes, and before submitting test messages to CDC.
 - All other jurisdictions should not plan to submit data to CDC or implement MMG-based updates to their surveillance information systems until the final MMGs (Stage III) have been posted.
- For more information about technical assistance:
 - Please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>.
 - For pilot jurisdictions: If you have questions specific to NMI TA, please contact Laura Carlton, APHL, at laura.carlton@aphl.org.
 - For non-pilot jurisdictions: If you have questions or would like to request TA through the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Cooperative Agreement, please email edx@cdc.gov.

For more information on NMI, please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>. If you have questions not answered in the FAQs, please send them to edx@cdc.gov.